Education and Training
- Ph.D., University of California at Davis, 2004
Nguyen, Quang N., David R. Martinez, Jonathon E. Himes, R. Whitney Edwards, Qifeng Han, Amit Kumar, Riley Mangan, et al. “Predominant envelope variable loop 2-specific and gp120-specific antibody-dependent cellular cytotoxicity antibody responses in acutely SIV-infected African green monkeys..” Retrovirology 15, no. 1 (March 9, 2018). https://doi.org/10.1186/s12977-018-0406-5.
Jones, Andrew T., Venkateswarlu Chamcha, Sannula Kesavardhana, Xiaoying Shen, David Beaumont, Raksha Das, Linda S. Wyatt, et al. “A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques..” Journal of Virology 92, no. 5 (March 2018). https://doi.org/10.1128/JVI.01796-17.
Fong, Youyi, Xiaoying Shen, Vicki C. Ashley, Aaron Deal, Kelly E. Seaton, Chenchen Yu, Shannon P. Grant, et al. “Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial..” The Journal of Infectious Diseases 217, no. 8 (March 2018): 1280–88. https://doi.org/10.1093/infdis/jiy008.
McGuire, Erin P., Youyi Fong, Christopher Toote, Coleen K. Cunningham, Elizabeth J. McFarland, William Borkowsky, Susan Barnett, et al. “HIV-Exposed Infants Vaccinated with an MF59/Recombinant gp120 Vaccine Have Higher-Magnitude Anti-V1V2 IgG Responses than Adults Immunized with the Same Vaccine..” Journal of Virology 92, no. 1 (January 2018). https://doi.org/10.1128/JVI.01070-17.
Wen, Yingxia, Hung V. Trinh, Christine E. Linton, Chiara Tani, Nathalie Norais, DeeAnn Martinez-Guzman, Priyanka Ramesh, et al. “Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant..” Plos One 13, no. 4 (January 2018). https://doi.org/10.1371/journal.pone.0194266.
Vaidya, Naveen K., Ruy M. Ribeiro, Pinghuang Liu, Barton F. Haynes, Georgia D. Tomaras, and Alan S. Perelson. “Correlation Between Anti-gp41 Antibodies and Virus Infectivity Decay During Primary HIV-1 Infection..” Frontiers in Microbiology 9 (January 2018). https://doi.org/10.3389/fmicb.2018.01326.
Seaton, Kelly E., Nathan A. Vandergrift, Aaron W. Deal, Wes Rountree, John Bainbridge, Eduard Grebe, David A. Anderson, et al. “Computational analysis of antibody dynamics identifies recent HIV-1 infection..” Jci Insight 2, no. 24 (December 21, 2017). https://doi.org/10.1172/jci.insight.94355.
Shen, Xiaoying, Rahul Basu, Sheetal Sawant, David Beaumont, Sue Fen Kwa, Celia LaBranche, Kelly E. Seaton, et al. “HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine..” Journal of Virology 91, no. 24 (December 2017). https://doi.org/10.1128/JVI.01077-17.
Saunders, Kevin O., Laurent K. Verkoczy, Chuancang Jiang, Jinsong Zhang, Robert Parks, Haiyan Chen, Max Housman, et al. “Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models..” Cell Reports 21, no. 13 (December 2017): 3681–90. https://doi.org/10.1016/j.celrep.2017.12.028.
Mayer, Kenneth H., Kelly E. Seaton, Yunda Huang, Nicole Grunenberg, Abby Isaacs, Mary Allen, Julie E. Ledgerwood, et al. “Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial..” Plos Medicine 14, no. 11 (November 14, 2017). https://doi.org/10.1371/journal.pmed.1002435.